Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin as Adjunct to Non-Surgical Treatment of Peri-Implantitis
NCT06715150Phase 4Not yet recruiting
- Sponsor
- Universidad de Santiago de Compostela
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in peri-implantitis comparing Azithromycin Group with Placebo Group (2 arms). Primary endpoint: Change in probing depth at 12 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
azithromycin
03
Conditions
peri-implantitis
Beyond the preview
Go deeper on NCT06715150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715150.